Table 1.
An overview of various characteristics of the vanD-positive Enterococcus faecium described in this report and the six previously described Dutch vanD-positive E. faecium isolates.
| Reference | Isolate | Resistance | Hospital day | MLST type | vanD type | Patient | MIC values (mg/L) | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Amoxicillin | Vancomycin | Teicoplanin | Linezolid | |||||||
| This report | VSE | ARE | 35 | Unknown | — | F | ≥32 | ≤0.5 | ≤0.5 | 2.0 |
| vanD-65 | VRE | 65 | 17 | vanD4 | F | ≥256 | 16 | 1.0 | 2.0 | |
| vanD-76 | VRE | 76 | 17 | vanD4 | F | ≥256 | 32 | 1.0 | 2.0 | |
| vanD-79 | VRE | 79 | 17 | vanD4 | F | ≥256 | 16 | 1.0 | 2.0 | |
| vanD-86 | VRE | 86 | 17 | vanD4 | F | ≥256 | 24 | 1.0 | 2.0 | |
| vanD-90 | VRE | 90 | 17 | vanD4 | F | ≥256 | 16 | 1.0 | 4.0 | |
| vanD-104 | VRE | 104 | 17 | vanD4 | F | ≥256 | 24 | 1.0 | 4.0 | |
| vanD-107 | VRE | 107 | 17 | vanD4 | F | ≥256 | 24 | 1.0 | ≥8.0 | |
| Top et al.17 | E7962 | VRE | 897 | vanD4 | A | >256 | 16 | <1 | N.R. | |
| E8043 | VRE | 203 | vanD4 | B | >256 | 16 | <1 | N.R. | ||
| E9242 | VRE | 262 | vanD2 | C | >256 | 256 | 4 | N.R. | ||
| E9352 | ARE | 117 | — | C | >256 | <1 | <1 | N.R. | ||
| E9353 | ARE | 117 | — | D | >256 | <1 | <1 | N.R. | ||
| E8429 | VRE | 1180 | vanD2 | D | >256 | 256 | 2 | N.R. | ||
| E9354 | VRE | 1281 | vanD2 | D | >256 | 256 | 2 | N.R. | ||
| E9641 | VRE | 1296 | vanD4 | E | >256 | 8 | <0.5 | N.R. | ||
Shown are MLST types, vanD subtypes and the MIC values for amoxicillin, vancomycin, teicoplanin, linezolid. MIC values for this report were determined by E-test for isolates 65–107. Only VITEK II data is known for the vancomycin-susceptible isolate of hospital day 35. The VRE isolates of day 65 through day 107 were re-evaluated by E-test (Shown is median of 3 independent measurements). VSE: vancomycin susceptible enterococcus, VRE: vancomycin resistant enterococcus, ARE: ampicillin resistant enterococcus. N.D.: not reported.